115 related articles for article (PubMed ID: 37873241)
1. IRF8-mutant B cell lymphoma evades immunity through a CD74-dependent deregulation of antigen processing and presentation in MHC CII complexes.
Qiu Z; Khalife J; Lin AP; Ethiraj P; Jaafar C; Chiou L; Huelgas-Morales G; Aslam S; Arya S; Gupta YK; Dahia PLM; Aguiar RCT
bioRxiv; 2023 Oct; ():. PubMed ID: 37873241
[TBL] [Abstract][Full Text] [Related]
2. Increased expression of IRF8 in tumor cells inhibits the generation of Th17 cells and predicts unfavorable survival of diffuse large B cell lymphoma patients.
Zhong W; Xu X; Zhu Z; Du Q; Du H; Yang L; Ling Y; Xiong H; Li Q
Oncotarget; 2017 Jul; 8(30):49757-49772. PubMed ID: 28537908
[TBL] [Abstract][Full Text] [Related]
3. IRF8 is associated with germinal center B-cell-like type of diffuse large B-cell lymphoma and exceptionally involved in translocation t(14;16)(q32.33;q24.1).
Tinguely M; Thies S; Frigerio S; Reineke T; Korol D; Zimmermann DR
Leuk Lymphoma; 2014 Jan; 55(1):136-42. PubMed ID: 23573829
[TBL] [Abstract][Full Text] [Related]
4. Generation and characterization of the Eµ-Irf8 mouse model.
Qiu Z; Holder KN; Lin AP; Myers J; Jiang S; Gorena KM; Kinney MC; Aguiar RCT
Cancer Genet; 2020 Jul; 245():6-16. PubMed ID: 32535543
[TBL] [Abstract][Full Text] [Related]
5. FOXP1 suppresses immune response signatures and MHC class II expression in activated B-cell-like diffuse large B-cell lymphomas.
Brown PJ; Wong KK; Felce SL; Lyne L; Spearman H; Soilleux EJ; Pedersen LM; Møller MB; Green TM; Gascoyne DM; Banham AH
Leukemia; 2016 Mar; 30(3):605-16. PubMed ID: 26500140
[TBL] [Abstract][Full Text] [Related]
6. Positive regulatory domain I (PRDM1) and IRF8/PU.1 counter-regulate MHC class II transactivator (CIITA) expression during dendritic cell maturation.
Smith MA; Wright G; Wu J; Tailor P; Ozato K; Chen X; Wei S; Piskurich JF; Ting JP; Wright KL
J Biol Chem; 2011 Mar; 286(10):7893-7904. PubMed ID: 21216962
[TBL] [Abstract][Full Text] [Related]
7. Loss of IRF8 Inhibits the Growth of Diffuse Large B-cell Lymphoma.
Xu Y; Jiang L; Fang J; Fang R; Morse HC; Ouyang G; Zhou JX
J Cancer; 2015; 6(10):953-61. PubMed ID: 26316891
[TBL] [Abstract][Full Text] [Related]
8. Epstein-Barr virus-positive diffuse large B-cell lymphoma features disrupted antigen capture/presentation and hijacked T-cell suppression.
Jiang XN; Yu BH; Yan WH; Lee J; Zhou XY; Li XQ
Oncoimmunology; 2020; 9(1):1683346. PubMed ID: 32002294
[No Abstract] [Full Text] [Related]
9. IRF8 is a transcriptional activator of CD37 expression in diffuse large B-cell lymphoma.
Elfrink S; Ter Beest M; Janssen L; Baltissen MP; Jansen PWTC; Kenyon AN; Steen RM; de Windt D; Hagemann PM; Hess C; van Spronsen DJ; Hoevenaars B; van der Spek E; Xu-Monette ZY; Young KH; Kaffa C; Bervoets S; van Heek J; Hesius E; de Winde CM; Vermeulen M; van den Brand M; Scheijen B; van Spriel AB
Blood Adv; 2022 Apr; 6(7):2254-2266. PubMed ID: 35086136
[TBL] [Abstract][Full Text] [Related]
10. Genomic Analyses Identify Recurrent Alterations in Immune Evasion Genes in Diffuse Large B-Cell Lymphoma, Leg Type.
Zhou XA; Louissaint A; Wenzel A; Yang J; Martinez-Escala ME; Moy AP; Morgan EA; Paxton CN; Hong B; Andersen EF; Guitart J; Behdad A; Cerroni L; Weinstock DM; Choi J
J Invest Dermatol; 2018 Nov; 138(11):2365-2376. PubMed ID: 29857068
[TBL] [Abstract][Full Text] [Related]
11. Adaptive T-cell immunity controls senescence-prone MyD88- or CARD11-mutant B-cell lymphomas.
Reimann M; Schrezenmeier J; Richter-Pechanska P; Dolnik A; Hick TP; Schleich K; Cai X; Fan DNY; Lohneis P; Maßwig S; Denker S; Busse A; Knittel G; Flümann R; Childs D; Childs L; Gätjens-Sanchez AM; Bullinger L; Rosenwald A; Reinhardt HC; Schmitt CA
Blood; 2021 May; 137(20):2785-2799. PubMed ID: 33232972
[TBL] [Abstract][Full Text] [Related]
12. Alterations in CIITA constitute a common mechanism accounting for downregulation of MHC class II expression in diffuse large B-cell lymphoma (DLBCL).
Cycon KA; Rimsza LM; Murphy SP
Exp Hematol; 2009 Feb; 37(2):184-194. PubMed ID: 19081173
[TBL] [Abstract][Full Text] [Related]
13. HLA dependent immune escape mechanisms in B-cell lymphomas: Implications for immune checkpoint inhibitor therapy?
Nijland M; Veenstra RN; Visser L; Xu C; Kushekhar K; van Imhoff GW; Kluin PM; van den Berg A; Diepstra A
Oncoimmunology; 2017; 6(4):e1295202. PubMed ID: 28507804
[TBL] [Abstract][Full Text] [Related]
14. Interferon regulatory factor 8 regulates pathways for antigen presentation in myeloid cells and during tuberculosis.
Marquis JF; Kapoustina O; Langlais D; Ruddy R; Dufour CR; Kim BH; MacMicking JD; Giguère V; Gros P
PLoS Genet; 2011 Jun; 7(6):e1002097. PubMed ID: 21731497
[TBL] [Abstract][Full Text] [Related]
15. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
16. Low GILT Expression is Associated with Poor Patient Survival in Diffuse Large B-Cell Lymphoma.
Phipps-Yonas H; Cui H; Sebastiao N; Brunhoeber PS; Haddock E; Deymier MJ; Klapper W; Lybarger L; Roe DJ; Hastings KT
Front Immunol; 2013; 4():425. PubMed ID: 24409177
[TBL] [Abstract][Full Text] [Related]
17. Frequent mutated B2M, EZH2, IRF8, and TNFRSF14 in primary bone diffuse large B-cell lymphoma reflect a GCB phenotype.
de Groen RAL; van Eijk R; Böhringer S; van Wezel T; Raghoo R; Ruano D; Jansen PM; Briaire-de Bruijn I; de Groot FA; Kleiverda K; Te Boome L; Terpstra V; Levenga H; Nicolae A; Posthuma EFM; Focke-Snieders I; Hardi L; den Hartog WCE; Bohmer LH; Hogendoorn PCW; van den Berg A; Diepstra A; Nijland M; Lugtenburg PJ; Kersten MJ; Pals ST; Veelken H; Bovée JVMG; Cleven AHG; Vermaat JSP
Blood Adv; 2021 Oct; 5(19):3760-3775. PubMed ID: 34478526
[TBL] [Abstract][Full Text] [Related]
18. The pathobiology of primary testicular diffuse large B-cell lymphoma: Implications for novel therapies.
Twa DDW; Mottok A; Savage KJ; Steidl C
Blood Rev; 2018 May; 32(3):249-255. PubMed ID: 29289361
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors activate CIITA and MHC class II antigen expression in diffuse large B-cell lymphoma.
Cycon KA; Mulvaney K; Rimsza LM; Persky D; Murphy SP
Immunology; 2013 Oct; 140(2):259-72. PubMed ID: 23789844
[TBL] [Abstract][Full Text] [Related]
20. FAS (CD95) mutations are rare in gastric MALT lymphoma but occur more frequently in primary gastric diffuse large B-cell lymphoma.
Wohlfart S; Sebinger D; Gruber P; Buch J; Polgar D; Krupitza G; Rosner M; Hengstschläger M; Raderer M; Chott A; Müllauer L
Am J Pathol; 2004 Mar; 164(3):1081-9. PubMed ID: 14982861
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
